An open pharmacokinetic study of hexylaminolevulinate-induced photodiagnosis after intravesical administration

Drugs in R and D

Volumn 7, Issue 3, 2006, Pages 173-186

  Collaud, S ^a,b   Jichlinski, P ^c   Marti, A ^c   Aymon, D ^c   Gurny, R ^a,b   Lange, N ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; HEXYLAMINOLEVULINATE; LEVULINIC ACID; PROTOPORPHYRIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SAFETY; FEMALE; FLUORESCENCE; HEMATOLOGY; HUMAN; KIDNEY FUNCTION; LABORATORY TEST; LIVER FUNCTION; MALE; PRIORITY JOURNAL; SKIN SENSITIVITY; SPECTROFLUOROMETRY; UROTHELIUM;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CYSTOSCOPY; DRUG STABILITY; FEMALE; FLUORESCENT DYES; HUMANS; MALE; MIDDLE AGED; SPECTROMETRY, FLUORESCENCE; URINARY BLADDER NEOPLASMS;

EID: 33745090525     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607030-00005     Document Type: Article

References (47)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000: the global picture. Eur J Cancer 2001 Sep; 37 Suppl. 8: 4-66
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004 Jan 1; 54 (1): 8-29
3. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999 Jan; 49 (1): 8-31
4. Herr HW. Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients. World J Urol 1997; 15 (2): 84-8
5. Raghavan D, Shipley WU, Garnick MB, et al. Biology and management of bladder cancer. N Engl J Med 1990 Apr 19; 322 (16): 1129-38
6. Droller MJ. Bladder cancer: state-of-the-art care. CA Cancer J Clin 1998 Sep 1; 48 (5): 269-84
7. Sternberg CN. A critical review of the management of bladder cancer. Crit Rev Oncol Hematol 1999 Aug; 31 (3): 193-207
8. Althausen AF, Prout Jr GR, Daly JJ. Non-invasive papillary carcinoma of the bladder associated with carcinoma in situ. J Urol 1976 Nov; 116 (5): 575-80
9. Smith G, Elton RA, Beynon LL, et al. Prognostic significance of biopsy results of normal-looking mucosa in cases of superficial bladder cancer. Br J Urol 1983 Dec; 55 (6): 665-9
10. Heney NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983 Dec; 130 (6): 1083-6
11. Flamm J, Dona S. The significance of bladder quadrant biopsies in patients with primary superficial bladder carcinoma. Eur Urol 1989; 16 (2): 81-5
12. Kriegmair M, Baumgartner R, Knuechel R, et al. Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. Urology 1994; 44 (6): 836-41
13. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997 Jun 15; 79 (12): 2282-308
14. Steinbach P, Kriegmair M, Baumgartner R, et al. Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. Urology 1994 Nov; 44 (5): 676-81
15. Chang SC, MacRobert AJ, Bown SG. Biodistribution of protoporphyrin IX in rat urinary bladder after intravesical instillation of 5-aminolevulinic acid. J Urol 1996 May; 155 (5): 1744-8
16. Zenzen V, Zankl H. Protoporphyrin IX-accumulation in human tumor cells following topical ALA- and h-ALA-application in vivo. Cancer Lett 2003 Dec 8; 202 (1): 35-42
17. Marti A, Jichlinski P, Lange N, et al. Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol 2003; 170 (2 Part 1): 428-32
18. Marti A, Lange N, van den Bergh H, et al. Optimisation of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J Urol 1999; 162 (2): 546-52
19. Lange N, Jichlinski P, Zellweger M, et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999; 80 (1/2): 185-93
20. van der Meijden AP, Sylvester R, Oosterlinck W, et al. EAU guidelines on the diagnosis and treatment of urothelial carcinoma in situ. Eur Urol 2005 Sep; 48 (3): 363-71
21. Jichlinski P, Guillou L, Karlsen SJ, et al. Hexyl aminolevulinate fluorescence cystoscopy: a new diagnostic tool for the photodiagnosis of superficial bladder cancer: a multicenter study. J Urol 2003 Jul; 170 (1): 226-9
22. Schmidbauer J, Witjes F, Schmeller N, et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol 2004 Jan; 171 (1): 135-8
23. Rick K, Sroka R, Stepp H, et al. Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood. J Photochem Photobiol B 1997 Oct; 40 (3): 313-9
24. Regula J, MacRobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX: a pilot study. Gut 1995 Jan; 36 (1): 67-75
25. Fiedler DM, Eckl PM, Krammer B. Does delta-aminolaevulinic acid induce genotoxic effects? J Photochem Photobiol B 1996 Mar; 33 (1): 39-44
26. Jichlinski P, Forrer M, Mizeret J, et al. Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results. Lasers Surg Med 1997; 20 (4): 402-8
27. Koenig F, McGovern FJ, Larne R, et al. Diagnosis of bladder carcinoma using protoporphyrin IX fluorescence induced by 5-aminolaevulinic acid. BJU Int 1999 Feb; 83 (1): 129-35
28. Kajiwara M, Hara K, Takatori K, et al. Revised structure of a delta-aminolevulinic acid derivative. Clin Chem 1993 Sep; 39 (9): 1867-71
29. Tomokuni K, Ichiba M, Hirai Y, et al. Optimized liquid-chromatographic method for fluorometric determination of urinary δ-aminolevulinic acid in workers exposed to lead. Clin Chem 1987; 33 (9): 1665-7
30. Oishi H, Nomiyama H, Nomiyama K, et al. Fluorometric HPLC determination of Δ-aminolevulinic acid (ALA) in the plasma and urine of lead workers: biological indicators of lead exposure. J Anal Toxicol 1996; 20 (2): 106-10
31. Hermanek P, Sobin J. UICC TNM classification of malignant tumours. 4th ed. Berlin: Springer Verlag, 1992
32. Mostofio FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. Geneva: World Health Organization, 1973
33. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992 Jul 30; 14 (4): 275-92
34. Wagnieres GA, Hadjur C, Grosjean P, et al. Clinical evaluation of the cutaneous phototoxicity of 5,10,15,20-tetra(m-hydroxyphenyl)chlorin. Photochem Photobiol 1998 Sep; 68 (3): 382-7
35. Dalton JT, Yates CR, Yin D, et al. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther 2002 May 1; 301 (2): 507-12
36. Gorchein A, Webber R. delta-Aminolaevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci (Lond) 1987 Jan; 72 (1): 103-12
37. Popken G, Schultze-Seemann W, Seiler KU, et al. Intravesical administration of 5-aminolevulinic acid (5-ALA). Eur J Clin Pharmacol 2000 Jul; 56 (3): 241-6
38. van den Boogert J, van Hillegersberg R, de Rooij FW, et al. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B 1998 Jun 15; 44 (1): 29-38
39. Doss M. Normal ranges of porphyrins and precursors in human tissue, urine and feces. In: Strik J, Koeman JH, editors. Chemical porphyrias in man. Amsterdam: Elsevier, 1979: 221: 221-32
40. Krems IJ, Spoerri PE. The pyrazines. Chem Rev 1947; 40: 290-358
41. Weast RC. CRC handbook of chemistry and physics. 8th ed. Boca Raton (FL): CRC Press, 1987
42. Kaliszewski M, Kwasny M, Kaminski J, et al. The stability of 5-aminolevulinic acid and its ester derivatives. Acta Pol Pharm 2004 Jan; 61 (1): 15-9
43. Novo M, Ĥuttemann G, Diddens H. Chemical instability of 5-aminolevulinic acid used in the fluorescence diagnosis of bladder tumours. J Photochem Photobiol B 1996 Jul; 34 (2-3): 143-8
44. Bunke A, Zerbe O, Schmid H, et al. Degradation mechanism and stability of 5-aminolevulinic acid. J Pharm Sci 2000 Oct; 89 (10): 1335-41
45. Gadmar OB, Moan J, Scheie E, et al. The stability of 5-aminolevulinic acid in solution. J Photochem Photobiol B 2002 Jul; 67 (3): 187-93
46. Franck B, Stratmann H. Condensation products of the porphyrin precursor 5-aminolevulinic acid. Heterocycles 1981; 15: 919-23
47. Butler AR, George S. The nonenzymatic cyclic dimerisation of 5-aminolevulinic acid. Tetrahedron 1992; 48: 7879-86